ArticleHuman mutation2026
Integrated Single-Cell and Bulk Transcriptomic Analysis Reveals an Endothelial Gene Signature Shaping EndMT and Prognosis in Hepatocellular Carcinoma.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors of the liver, with increasing incidence and mortality rates globally. This study investigates the role of endothelial cells (ECs) in the progression of HCC, particularly focusing on the process of endothelial-to-mesenchymal transition (EndMT) and its underlying molecular mechanisms. Methods: We utilized single-cell RNA sequencing (scRNA-seq) and multiomics analyses to explore the involvement of ECs in HCC and their transformation mechanisms. The study emphasized the potential application of EC-related genes (ECRGs) in prognostic evaluation for HCC patients. Furthermore, HCC organoids were utilized to validate the functional relevance of selected ECRGs. Results: ECs play a critical role in the progression of HCC, particularly through mechanisms related to EndMT and its influence on patient prognosis. We identified 19 key ECRGs that are pivotal to the initiation and development of HCC and constructed a robust prognostic model using LASSO regression analysis. Notably, this gene signature effectively stratifies HCC subtypes and reveals significant differences in immune cell infiltration and immune checkpoint gene expression among EC-related prognostic groups, underscoring its potential relevance in guiding immunotherapy, sorafenib therapy, and transarterial chemoembolization (TACE) outcomes. Furthermore, the coculture system of HCC and vascular organoids successfully mimicked the EndMT process, revealing spatial colocalization of three ECRGs-MPZL2, KITLG, and PCDH1-with established EndMT markers, suggesting their potential as therapeutic targets in tumor-associated endothelial plasticity. Conclusions: This study emphasizes ECs' role in HCC progression and how EndMT affects prognosis. HCC organoids revealed ECRGs linked to EndMT, like MPZL2, KITLG, and PCDH1, as potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.